PROBLEM TO BE SOLVED: To provide: peptides, nucleic acids and cells for use in immunotherapy of cancer； and tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses.SOLUTION: The present invention relates to novel peptides with amino acid sequence TLSSIKVEV and their variants, derived from HLA class I and HLA class II molecules of human tumor cells. The peptides have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class I or II.SELECTED DRAWING: None【課題】がんの免疫療法で使用するためのペプチド、核酸、及び細胞の提供。単独で、又はその他の腫瘍関連ペプチドとの組み合わせで、抗腫瘍免疫応答を刺激するワクチン組成物の活性医薬品成分の役割を果たす、腫瘍関連細胞傷害性Ｔ細胞（ＣＴＬ）ペプチドエピトープの提供。【解決手段】ヒト腫瘍細胞のＨＬＡクラスＩ及びＨＬＡクラスＩＩ分子に由来する新規ペプチドのうち、アミノ酸配列ＴＬＳＳＩＫＶＥＶのものと、それらの変異型。ヒト主要組織適合性複合体（ＭＨＣ）のクラスＩ又はクラスＩＩ分子に結合する能力を有するペプチド。【選択図】なし
